Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Aytu Biopharma
WARNING LETTER
•Aytu Biopharma

Aytu Biopharma – FDA Warning Letter

Record Details

Aytu Biopharma (Aytu) received a warning letter from the FDA on September 9, 2025, following an inspection of their promotional communications for COTEMPLA XR-ODT (methylphenidate extended-release orally disintegrating tablets), conducted as part of the FDA"s monitoring and surveillance program. The inspection revealed that Aytu"s sponsored links for COTEMPLA XR-ODT were misleading and violated the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Key violations included the omission of critical risk information, creating a misleading impression of the drug"s safety and efficacy. The promotional materials failed to adequately communicate the high potential for abuse and misuse associated with COTEMPLA XR-ODT, a Schedule II controlled substance. Additionally, the links falsely suggested therapeutic equivalence with Concerta, despite differences in dosage form and strength, misleading consumers about substitutability.

The FDA also noted that the sponsored links did not prominently present the established name of the drug alongside its proprietary name, further misbranding the product. Moreover, Aytu failed to submit the promotional materials under Form FDA-2253, as required by FDA regulations.

The FDA has requested Aytu to cease the dissemination of these misleading promotional communications immediately and to submit a comprehensive plan to address these violations. Aytu must ensure future compliance with all regulatory requirements to prevent further misbranding of their products.

Company
Aytu Biopharma
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · da03778b-a7c6-493c-8791-a13688f45f21

Violation Codes9
21 U.S.C. 352(a)21 U.S.C. 352(e)(1)(B)21 U.S.C. 352(n)21 U.S.C. 321(n)21 CFR 201.10(g)(1)21 CFR 202.1(b)(1)21 CFR 202.1(e)(5)21 CFR 314.81(b)(3)(i)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Aytu Biopharma
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.